Overview
Discounted cash flow
Income / accounting-based
Multiples & assets
Scenario
Toolbox
Weighted blend
$352.67
+139.72% vs spot
Strong Buy
Spot price
$147.12
Mkt cap $53.3B
subtle cardAnalyst PT consensus
$172.85
+17.49% vs spot
subtle cardMethods covered
18 / 19
15 in blend
subtle cardFootball field
BDX · fair-value range by method
Method comparison
BDX · fair value by valuation framework
| Method | Category | Fair value | Range | vs spot | Weight | Driver | Conf. |
|---|---|---|---|---|---|---|---|
| DCF · FCFF | dcf | $774.28 | $457.74 – $1,563.74 | +426.29% | 22.3% | WACC 4.4%, g₀=25.0%, gₗ=2.0% | high |
| DCF · FCFE | dcf | $422.22 | $290.25 – $663.53 | +186.99% | 16.8% | kₑ 5.7%, g₀=25.0%, gₗ=2.0% | high |
| DDM · Gordon | ddm | $88.92 | $70.13 – $121.48 | -39.56% | — | D₁ 3.25, kₑ 5.7%, gₗ 2.0% | med |
| DDM · H-model | ddm | $189.18 | $138.88 – $276.31 | +28.59% | — | D₀ 3.25, g₀=25.0%, gₗ=2.0%, H 5y | med |
| DDM · multi-stage | ddm | $147.30 | $125.20 – $169.39 | +0.12% | 5.6% | 5y schedule 25.0% → 2.0%, kₑ 5.7% | high |
| Residual income | income | $70.43 | $61.98 – $78.89 | -52.12% | 11.2% | BV 69.05, ROE 6.6% → kₑ | high |
| EVA / MVA | income | $502.15 | $441.89 – $562.40 | +241.32% | 7.8% | IC 43.7B, WACC 4.4% | high |
| P/E · sector | multiple | $128.26 | $112.87 – $143.65 | -12.82% | 13.4% | EPS 5.83 × peer P/E 22.0 | med |
| P/S · sector | multiple | $237.58 | $201.94 – $273.22 | +61.49% | 3.4% | Rev/sh 59.40 × peer P/S 4.00 | med |
| EV / EBITDA | multiple | $152.37 | $134.09 – $170.66 | +3.57% | 11.2% | EBITDA × peer 15.0× − ND 18.3B | high |
| EV / EBIT | multiple | $76.35 | $64.90 – $87.81 | -48.10% | 2.2% | EBIT × peer 18.0× − ND | med |
| EV / Sales | multiple | $152.09 | $129.28 – $174.91 | +3.38% | 2.2% | Sales × peer 3.40× − ND | med |
| PEG-anchored | multiple | $233.20 | $198.22 – $268.18 | +58.51% | 1.1% | PEG=1, fwd EPS g 115.8% | med |
| Earnings power | intrinsic | $84.76 | $74.59 – $94.93 | -42.39% | 0.6% | NOPAT / WACC, no growth | med |
| Graham revised | intrinsic | $278.95 | $237.11 – $320.79 | +89.61% | 0.6% | EPS×(8.5+2g)·4.4/Y | low |
| Lynch P/E=g | intrinsic | $145.75 | $123.89 – $167.61 | -0.93% | 0.6% | PE = g (25.0) | low |
| Book NAV | asset | $69.05 | $65.60 – $72.50 | -53.07% | 1.1% | (Assets − Liabilities) / Shares | high |
| Liquidation | asset | $24.60 | $20.91 – $28.30 | -83.28% | — | Cash 100% + non-cash 70% − Liab. | low |
| Reverse DCF | reverse | — | — | — | — | Implied g -7.4% · Pessimistic — market pricing decline | high |
Cost-of-capital build-up
CAPM cost of equity, after-tax cost of debt, WACC. Risk-free as of 2026-05-12.
| Risk-free rate (US 10y Treasury)rf | 4.46% |
| Equity beta (0.28)β | × 0.28 |
| Equity risk premiumERP | 4.46% |
| Cost of equity (CAPM)kₑ | 5.73% |
| Pre-tax cost of debtkd | 3.20% |
| Effective tax ratet | 14.8% |
| After-tax cost of debt | 2.72% |
| Equity weight$25.4B | 57.0% |
| Debt weight$19.2B | 43.0% |
| WACC | 4.44% |
Growth assumptions
Blended forward growth used as DCF default; terminal pegged to long-run nominal GDP.
| Analyst forward revenue growthFMP | -12.07% |
| Analyst forward EPS growthFMP | 115.84% |
| Historical 5y revenue CAGRFY | 3.37% |
| Historical 5y EPS CAGRFY | -3.95% |
| Sustainable g (ROE × retention)Δ | 1.90% |
| Blended near-term growth (g₀) | 25.00% |
| Terminal growth (gₗ) | 2.00% |
Sources
- FMP /analyst-estimates— 8 rows(as of 2023-09-30)
- Treasury rates · 10y— 4.46% rf(as of 2026-05-12)
- market_risk_premium · DB— 4.46% ERP(as of 2026-05-13)
- Sector multiple defaults— Healthcare (live sector PE unavailable)
- FMP /price-target-consensus— mean $172.85
This page is generated by a quantitative valuation engine for research purposes only and does not constitute investment advice. Methodology follows standard CFA / Damodaran frameworks; assumptions are driven by analyst consensus from Financial Modeling Prep and reported financial statements.